Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Naval Daver

Leukemia · MD Anderson Cancer Center

View

Dr. Daniel Pollyea

Leukemia · CU Anschutz Medical Campus

View

Dr. Jessica Altman

Leukemia · Northwestern Medicine

View

Dr. Shella Saint Fleur-Lominy

Leukemia · UMSOM

View

Dr. Azra Raza

Leukemia · CUIMC

View

Dr. Molly Imgruet

Leukemia · Stanford

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    CLDr. Curtis Lachowiez

    Dr. Curtis Lachowiez

    Hematology & Oncology · Leukemia
    Oregon Health and Science University Hospital
    curtisl

    Research

    Rapid Clonal Selection Within Early Hematopoietic Cell Compartments Presages the Outcome of Ivosidenib Combination Therapy

    2026

    Via Blood

    Research

    Models, Models, Everywhere: But Which One Should Guide Care?

    2026

    Via Blood Cancer Discovery

    Research

    HMA+VEN Triplet Regimens for the Initial Treatment of AML in Adults (PRO)

    2026

    Via Blood Advances

    Research

    Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model

    2026

    Via Journal of Clinical Oncology

    Research

    Treatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based Therapy

    2025

    Via JCO Oncology Practice

    Research

    Genetic and Phenotypic Correlates of Clinical Outcomes With Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study

    2025

    Via Blood Cancer Discovery

    Research

    Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML

    2025

    Via Journal of Clinical Oncology

    Research

    Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification Across Disease States

    2025

    Via Blood Cancer Discovery

    Research

    Ivosidenib or Venetoclax Combined With Hypomethylating Agents in IDH1-Mutated Acute Myeloid Leukemia: A Real-World Study

    2025

    Via Blood Neoplasia

    Research

    Olutasidenib: An Achilles' Heel for IDH1-Mutated MDS?

    2025

    Via Blood Advances

    Research

    Optimizing Lower Intensity Triplet Therapy in Acute Myeloid Leukemia: A Practical Guide

    2025

    Via Blood Cancer Journal

    Research

    A Rapid Gene Expression Profiler Classifies AML Tumor Responsiveness to Standard Therapies

    2025

    Via bioRxiv (preprint)

    Research

    Thromboprophylaxis With Intermediate Dose Enoxaparin During Asparaginase Containing Induction for Young Adults With Acute Lymphoblastic Leukemia

    2024

    Via Leukemia & Lymphoma

    Research

    Refined ELN 2024 Risk Stratification Improves Survival Prognostication Following Venetoclax-Based Therapy in AML

    2024

    Via Blood

    Research

    Mutation- and MRD-Informed Treatments for Transplant-Ineligible Patients

    2024

    Via Hematology (American Society of Hematology Education Program)